KU-55933 (ATM Kinase Inhibitor)

Catalog No.S1092

KU-55933 (ATM Kinase Inhibitor) Chemical Structure

Molecular Weight(MW): 395.49

KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.

Size Price Stock Quantity  
In DMSO USD 112 In stock
USD 70 In stock
USD 120 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 36 Publications

4 Customer Reviews

  •  

    Effects of NVP-BKM120 and KU-55933 and their combination on the DNA damage response. A, HCC1937 cells were treated for 18 hours with NVP-BKM120 at 2.5 μmol/L, KU-55933 at 10 μmol/L, or their combination, subjected to ionizing radiation(IR) with 10 Gy or mock, lysed 6 hours later, and subjected to immunoblotting with antibodies as indicated.

    Cancer Discov 2012 2, 1048-1063. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

    Confocal immunostaining (left panel) graphical representation (right panel) for phosphorylation of S25-53BP1, which is known to be ATM dependent, at different time points following irradiation of HEK 293T parental and p18CycE-expressing cells in the absence or presence of the ATM inhibitor, KU55933. Error bars represent SD (n=3).

    Nucleic Acids Res 2011 41, 10157-69. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

  •  

    59PDb2 repression is restored in c22 by inhibition of DNAPKcs. Shown are representative ChIP QPCR of USF-1 binding at Db2 (A) and Db2 mRNA levels (B) in P5424-c22 1 d after treatment with the indicated kinase inhibitors.

    J Immunol 2012 188, 2266-2275. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

    effect of ATM inhibitor in etoposide-induced cell death. The cells were pretreated with KU55933 (2 μM) for 1 h before etoposide treatment.

     

     

    J Biol Chem 2011 286, 8394-8404. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

Purity & Quality Control

Choose Selective ATM/ATR Inhibitors

Biological Activity

Description KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.
Targets
ATM [1]
(Cell-free assay)
12.9 nM
In vitro

KU-55933 inhibits DNA-PK and PI3K with IC50 of 2.5 μM and 16.6 μM, respectively. Besides, KU-55933 also prevents the activity of mTOR with IC50 of 9.3 μM. KU-55933 is active at the cellular level in ablating a well-characterized ATM-dependent phosphorylation event. KU-55933 has a dose-dependent effect in inhibiting this ATM-dependent phosphorylation event with IC50 of 300 nM. KU-58050 does not prevent the ATM-dependent phosphorylation of p53 serine 15 until a dose of 30 μM. Addition of KU-55933 has no appreciable effects on UV-induced phosphorylation of H2AX on serine 139, NBS1 on serine 343, CHK1 on serine 345, and SMC1 on serine 966. In stark contrast to the UV responses, KU-55933 ablates the ionizing radiation-induced phosphorylation of these ATM substrates. KU-55933 sensitizes HeLa cells to a range of ionizing radiation doses. [1] KU-55933 inhibits the phosphorylation of Akt induced by growth factors in cancer cells. KU-55933 suppresses the proliferation of cancer cells. Furthermore, suppression of ATM by KU-55933 improves survival, probably via prevention of downstream activation of TAp63α. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
DU-145 M33mUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLmTYpKSzVyPUOuNlc{PTJizszN M4HF[3NCVkeHUh?=
HuO-3N1 M3r0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HvXWlEPTB;ND6xO|E1OiEQvF2= M4HlNHNCVkeHUh?=
LAMA-84 MnSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIq5cHlKSzVyPUSuOVg1PjVizszN M3nlXHNCVkeHUh?=
CAL-72 NHLuU2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTVwNEiwPFQh|ryP NXzPNGE2W0GQR1XS
LoVo NVu1SZJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fF[WlEPTB;Nj65N|I{QSEQvF2= MkH6V2FPT0WU
HH NWW5N3FUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlmxTWM2OD16LkK3OlcyKM7:TR?= MWPTRW5ITVJ?
SK-MEL-3 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\YTWM2OD16LkK4OVc2KM7:TR?= MXXTRW5ITVJ?
KM12 NHrKWm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPpTWM2OD17LkKxNVQzKM7:TR?= NHu1RWhUSU6JRWK=
NCI-H1437 M4fEOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDpTWM2OD17LkiwPVch|ryP NGfqeGlUSU6JRWK=
NCI-H1838 NWHZTnNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYq2WWQ2UUN3ME2xNU4yQDZ3IN88US=> Ml3BV2FPT0WU
J-RT3-T3-5 NIPjUFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fIbGlEPTB;MUGuNlQyPyEQvF2= M3XXR3NCVkeHUh?=
GOTO NYHLXoZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnhXmdMUUN3ME2xNU43QTl4IN88US=> M2DxUXNCVkeHUh?=
LB2241-RCC M2TkO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTFzLkexPFYh|ryP NHHhdmRUSU6JRWK=
ES7 NES1TIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fLVWlEPTB;MUGuO|g5KM7:TR?= MUjTRW5ITVJ?
KP-N-YS MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37SNmlEPTB;MUKuOlM2PCEQvF2= MoS3V2FPT0WU
CAL-12T MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXBcnZKSzVyPUGzMlYyPyEQvF2= NV3zSW5PW0GQR1XS
COLO-684 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHHTWM2OD1zND6xOVY6KM7:TR?= MVjTRW5ITVJ?
DOK M2jONWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml[wTWM2OD1zNT6zN|I6KM7:TR?= Mln6V2FPT0WU
Hs-578-T NGrkNmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXi3OFZbUUN3ME2xOU41OTh{IN88US=> M4DqTnNCVkeHUh?=
D-423MG M{nqb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFu1V5NKSzVyPUG1MlUzOzZizszN NEXLNYJUSU6JRWK=
DBTRG-05MG NEDVUYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTF3Lk[xNVEh|ryP Mnf2V2FPT0WU
VM-CUB-1 NH3E[2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTF3Lkm4OFkh|ryP MUDTRW5ITVJ?
KG-1 NVTLUHd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHLV|lHUUN3ME2xOk4xQTl4IN88US=> M2rMWHNCVkeHUh?=
8305C M4exbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jCNGlEPTB;MU[uNVg5QSEQvF2= MlPlV2FPT0WU
HuH-7 MnPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTF4LkK2O|Qh|ryP M3jRbHNCVkeHUh?=
LXF-289 MmXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;afmlEPTB;MU[uNlc1PyEQvF2= NFHwfHlUSU6JRWK=
NCI-H1793 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTF4LkS3NVIh|ryP MVHTRW5ITVJ?
ChaGo-K-1 M17JNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2ntPGlEPTB;MU[uOlU3QCEQvF2= MkTyV2FPT0WU
GCIY M2TTbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTF4Lke5NFUh|ryP M2qxPXNCVkeHUh?=
SK-MEL-28 NYHP[|hUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTF5LkC0O|Uh|ryP M1fzdXNCVkeHUh?=
NCI-SNU-1 Ml\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LQVmlEPTB;MUeuNVI3QSEQvF2= MX;TRW5ITVJ?
CTB-1 MmLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTF5LkKyOVkh|ryP M3LQNnNCVkeHUh?=
NCI-H82 MnnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7NZ4pDUUN3ME2xO{41PTd|IN88US=> Ml3uV2FPT0WU
HCC2998 NX\p[Gt{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TLVmlEPTB;MUeuOlc{OyEQvF2= NV;vVpE2W0GQR1XS
NCI-H2030 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{[1[mlEPTB;MUiuNVk6PyEQvF2= NFLsNnpUSU6JRWK=
HuP-T3 NFLnSWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTF6LkW4PFgh|ryP MUXTRW5ITVJ?
697 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTF7LkCyNFEh|ryP MUTTRW5ITVJ?
MLMA NF\lU3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7LVIpKSzVyPUG5MlA2PTdizszN NXTlcIl5W0GQR1XS
HCC70 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnO3TWM2OD1zOT60PFkh|ryP NUDIfHJ[W0GQR1XS
A704 MoTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HTN2lEPTB;MUmuPFMxPSEQvF2= NFLQVGtUSU6JRWK=
D-283MED Mmm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXYd3BzUUN3ME2yNE42OzN7IN88US=> NH7KUYdUSU6JRWK=
U031 MmLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTJzLkG0PFkh|ryP M{nDTnNCVkeHUh?=
HSC-3 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTJzLkG4N|Uh|ryP NFfmOY5USU6JRWK=
JVM-3 M3jVSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoL6TWM2OD1{Mj61NFYh|ryP MkHaV2FPT0WU
Mewo MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13rc2lEPTB;MkKuOVA4OyEQvF2= MVjTRW5ITVJ?
YH-13 NEmz[nZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7jTWM2OD1{Mj61NVI{KM7:TR?= MkewV2FPT0WU
LB1047-RCC NXmyW|VwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnnTWM2OD1{Mj61PFc6KM7:TR?= NFLHe3NUSU6JRWK=
HCC2157 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDlWFJ1UUN3ME2yNk45ODV2IN88US=> NFLaTWFUSU6JRWK=
SNU-449 MkHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTJ{Lki3OFgh|ryP Mn\rV2FPT0WU
Ramos-2G6-4C10 Mnj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTJ{Lkm2JO69VQ>? MX7TRW5ITVJ?
CHL-1 M3TpRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULuNo5[UUN3ME2yN{44Ojl{IN88US=> MojUV2FPT0WU
SK-MEL-30 NXHESWptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPMUoxKSzVyPUK0MlQ3PjJizszN MWDTRW5ITVJ?
PANC-08-13 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInEbGlKSzVyPUK1MlA6OzhizszN MljBV2FPT0WU
QIMR-WIL MoLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3z4[2lEPTB;MkWuNVg2QCEQvF2= MkfoV2FPT0WU
BFTC-905 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\2eWZFUUN3ME2yOU42QTR2IN88US=> MkX6V2FPT0WU
GI-1 MnThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmL2TWM2OD1{NT63NFU2KM7:TR?= NYO1S|BnW0GQR1XS
MDA-MB-415 M1nndGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTJ4LkWwN|Mh|ryP NGLlZoJUSU6JRWK=
GT3TKB NInTRXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTJ4LkWzOFIh|ryP M{jVNHNCVkeHUh?=
DEL M3rISmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVT6OmxQUUN3ME2yOk45OzV4IN88US=> NWSze5V7W0GQR1XS
KOSC-2 NYGxO|NOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvYSnJKSzVyPUK2MlkxPzVizszN Mnm2V2FPT0WU
RVH-421 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGezTYJKSzVyPUK3MlI6OjFizszN MnX4V2FPT0WU
EW-13 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PSNGlEPTB;MkeuOFMxQCEQvF2= MYLTRW5ITVJ?
639-V MkPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTJ5LkWxNVkh|ryP NY\oW4d7W0GQR1XS
A2780 MmL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fMcGlEPTB;MkeuOlQyKM7:TR?= MWLTRW5ITVJ?
SW982 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYf4ZZQ1UUN3ME2yO{46ODV{IN88US=> NWPDTWFtW0GQR1XS
SW1710 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTJ6LkC5PFEh|ryP NU\p[VBMW0GQR1XS
HCC1569 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7FdJFKSzVyPUK4MlQ5QTdizszN MorKV2FPT0WU
MV-4-11 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13INGlEPTB;MkiuOVc{PSEQvF2= NXHFTXlTW0GQR1XS
BHT-101 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M16yVmlEPTB;MkiuOlU4OiEQvF2= NX;BfIJMW0GQR1XS
Ca9-22 M4nx[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\YTWM2OD1{OD63NVQh|ryP M36wfnNCVkeHUh?=
HAL-01 NH;kXWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXznbpF7UUN3ME2yPE44PjF3IN88US=> NXTWSWNpW0GQR1XS
D-263MG NF7DUYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4r0cmlEPTB;MkmuN|Q1KM7:TR?= NWLvdohOW0GQR1XS
NEC8 NUf0fog1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPkd2dKSzVyPUK5MlU2PDhizszN NYHvb|lQW0GQR1XS
EKVX MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTNzLkW4OFch|ryP Ml\YV2FPT0WU
EM-2 NUDHS4JjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4P4ZmlEPTB;M{GuOlMxPCEQvF2= MlHyV2FPT0WU
MFM-223 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfQc4xqUUN3ME2zNU45ODl6IN88US=> MWfTRW5ITVJ?
SK-PN-DW Mn7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlexTWM2OD1|Mj6xOFA3KM7:TR?= MULTRW5ITVJ?
HuO9 NVG1ZpQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3CTWM2OD1|Mj61NlgzKM7:TR?= MonhV2FPT0WU
MHH-PREB-1 MmOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLpTWM2OD1|Mj62NlM1KM7:TR?= MYjTRW5ITVJ?
OVCAR-4 NXrRcnFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTN{LkizOlMh|ryP MojNV2FPT0WU
NCI-H1648 NFf5UVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTN{Lki2OVEh|ryP MWfTRW5ITVJ?
MKN1 NIDEO|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXIN4xVUUN3ME2zOE4yOTBzIN88US=> M3fPN3NCVkeHUh?=
KYSE-450 NG\kVHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIe3O3pKSzVyPUO0MlY1PDRizszN M1\PRnNCVkeHUh?=
ES8 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnDXZNWUUN3ME2zOE45QTd3IN88US=> MXLTRW5ITVJ?
MS-1 M4nvVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljWTWM2OD1|ND65OVU1KM7:TR?= Mnf5V2FPT0WU
HOP-92 Mn3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvrWGZKSzVyPUO1MlkzPzdizszN M{TVbnNCVkeHUh?=
SKG-IIIa M4T3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTN4LkK1OlEh|ryP MnLkV2FPT0WU
TE-11 NY\lSWtJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\hWVk6UUN3ME2zOk42OjR|IN88US=> M1W5VHNCVkeHUh?=
SK-NEP-1 M1TGcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfSR4xkUUN3ME2zO{43PzR2IN88US=> NGL5XpRUSU6JRWK=
DB Ml;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTnO41iUUN3ME2zO{46OTh3IN88US=> MUfTRW5ITVJ?
IA-LM M{X6UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTXTWM2OD1|OD6wNlM6KM7:TR?= MnXrV2FPT0WU
COLO-829 Mly1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTN6LkSxOVkh|ryP MoHiV2FPT0WU
TGBC11TKB NYrCfWU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTN7LkG0NFgh|ryP NWXKbYppW0GQR1XS
CAL-51 NIXMO4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHhTWM2OD12MD6wOlEzKM7:TR?= NVXtNYxtW0GQR1XS
NCI-H2228 NFLKeHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTRyLkO2OlIh|ryP Mn7MV2FPT0WU
C32 M1zBNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDXcYxGUUN3ME20NE41ODJ2IN88US=> NHf0UmpUSU6JRWK=
KU-19-19 MkXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfiW4RGUUN3ME20NE44Pjh|IN88US=> M4\CNHNCVkeHUh?=
KNS-62 MknZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXpZWZWUUN3ME20NE45OzhzIN88US=> MXLTRW5ITVJ?
FADU NFjaWIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTRzLkK1NFIh|ryP M2XBUXNCVkeHUh?=
CAL-33 M37Mfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPscZJKSzVyPUSyMlY4PDlizszN NUi1W41jW0GQR1XS
CHP-134 Ml35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7yXVZvUUN3ME20Nk45PDl4IN88US=> M2HCU3NCVkeHUh?=
HDLM-2 MlXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zpZmlEPTB;NEKuPVA5PCEQvF2= NVLmZ5VkW0GQR1XS
NBsusSR MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTR|LkC3NlUh|ryP NHvi[25USU6JRWK=
SW954 NV3UPFdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvaTWM2OD12Mz6xNFU{KM7:TR?= MlTwV2FPT0WU
HCC1806 NUfBdXBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPDUpZ6UUN3ME20N{41OTFizszN Mn\6V2FPT0WU
VMRC-RCZ NF\6cWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jjNGlEPTB;NEOuOFU5PiEQvF2= NWDpNXdqW0GQR1XS
A549 NX7ESplYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfadYpKSzVyPUSzMlk{OSEQvF2= MY\TRW5ITVJ?
NKM-1 M2jtOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTR|Lkm1OVgh|ryP MkmwV2FPT0WU
DMS-273 NGrUXlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDQWmM5UUN3ME20OE44PTZ5IN88US=> MlXFV2FPT0WU
TYK-nu MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HuRmlEPTB;NEWuNVI{PCEQvF2= M2TTd3NCVkeHUh?=
KALS-1 M3LQemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\PTWM2OD12NT6xOFYh|ryP NGPuWWFUSU6JRWK=
A101D NIPl[olIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHacppVUUN3ME20OU41PDV4IN88US=> NVvWV3Z3W0GQR1XS
G-361 NGrZc3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorFTWM2OD12Nj6yNVM5KM7:TR?= M4jnUnNCVkeHUh?=
KARPAS-299 NHvFSnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1r3RmlEPTB;NE[uN|UyPiEQvF2= MkPVV2FPT0WU
RS4-11 MnTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;HZWlEPTB;NE[uOVQzKM7:TR?= M1n6O3NCVkeHUh?=
HT-1376 NEj3XoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWi0XYNIUUN3ME20Ok44PDJ4IN88US=> MYTTRW5ITVJ?
SK-N-AS MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1P0dGlEPTB;NE[uO|gzOiEQvF2= Mmq0V2FPT0WU
MG-63 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fmfGlEPTB;NE[uPVA{PiEQvF2= M4P0RnNCVkeHUh?=
EPLC-272H MnHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;LeZlsUUN3ME20Ok46PTB|IN88US=> NH\WblJUSU6JRWK=
BALL-1 NUfu[2xWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfKdZZKSzVyPUS3Mlg{OiEQvF2= NGX5O4dUSU6JRWK=
LCLC-97TM1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHX1blNKSzVyPUS4MlIxOiEQvF2= MkHUV2FPT0WU
HO-1-N-1 NV7qcGh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nuZmlEPTB;NEiuPVY4PiEQvF2= Mn;ZV2FPT0WU
MFE-280 NVK0fZQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGraT5hKSzVyPUS5MlQ3OTdizszN M4n4V3NCVkeHUh?=
NCI-H526 NWHUc2d1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLiR49oUUN3ME20PU45OTZ|IN88US=> NEPndFBUSU6JRWK=
D-566MG NUnMdlBjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7lV25KSzVyPUS5MlkxQTZizszN MnTIV2FPT0WU
BB30-HNC MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\oUpRCUUN3ME20PU46PDl6IN88US=> MUTTRW5ITVJ?
SK-N-DZ NYHKNXltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTVyLkC0PFEh|ryP MX\TRW5ITVJ?
HepG2  NHLw[YlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXvNG81OTEEoN88US=> NG\4O5QzPCCq MUPicI9kc3NiU1OtTWlKOy2rbnT1Z4VlKFNicHjhd4Uh[XK{ZYP0 Mlr5NlU2OjdzMkO=
HepG2  NWXTbGpCTnWwY4Tpc44hSXO|YYm= M3jo[lExyqEQvF2= NWDjSJo{OjRiaB?= M3y0d5N2eHC{ZYPz[ZMhfGinIIDoc5NxcG:{eXzheIlwdnNib3[gRXROKG:wIGPldlE6QDFuIFPob|Ehd25iU3XyN|Q2NCCFaHuyJI9vKFSqck[4MEBidmRiQ3TrNkBwdiCWeYKxOUBqdmS3Y3XkJIJ6KFOFLVnJTVM> NUf4Rox1OjV3MkexNlM>
KATO III  MnT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nDNFIvPS93L{euOUDPxE1? NHvBelVFVVOR Ml;Q[Y5p[W6lZYOgeIhmKHSxeHnjbZR6KG:oIH;sZZBiemmk M{DGdlI1QDRzN{G4
hTCEpi MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HnR|ExKM7:TR?= NWHHOoJtTE2VTx?= MnL3dJJmfmWwdIOgeIhmKGO7dH;wZZRpcWNiZX\m[YN1KG:oIFjTWk0y MUiyOFM4ODh|NR?=
MCF10A M1HJ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV36OW43OTBizszN M4r2eFI1KGh? NXP1dYl4TE2VTx?= MWnwc5RmdnSrYYTld{B1cGViY4n0c5RwgGmlaYT5JI9nKEeD M1\EclI1OTVyNUm1
HL-60  NVrxW41KTnWwY4Tpc44hSXO|YYm= NVvOXWRTOTBizszN NGr4eWMxNjViaB?= M3XlOmROW09? M2GwdpJm\HWlZYOgdIhwe3Cqb4L5cIF1cW:wIH;mJGNpczMEoB?= MYeyN|k{PDRzMR?=
MCF-7 NX76WW96T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFu3Rm0yNTFyMN88US=> NX[4N4RiOjRiaB?= MYrGRnM> NGHwNGxqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:w NW\5TYFTOjNzOEWzOFc>
HeLa  MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Ph[VEuOTByzszN MmSxNlQhcA>? NUPjOIZvTkKV MYrpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9v MoDmNlMyQDV|NEe=
SH-SY5Y MXHGeY5kfGmxbjDBd5NigQ>? M2XufFExyqEQvF5CpC=> NEHP[mQzPCCq MnTPbY5pcWKrdIOgZ4xqd3G3aX7vcE1qdmS3Y3XkJJBpd3OyaH;yfYxifGmxbjDv[kBxPTN? MlXGNlI3Ojd{OUS=
IMR-32 NHzlUWFHfW6ldHnvckBCe3OjeR?= MYixNOKh|ryPwrC= NWO4c3dMOjRiaB?= MmH6bY5pcWKrdIOgZ4xqd3G3aX7vcE1qdmS3Y3XkJJBpd3OyaH;yfYxifGmxbjDv[kBxPTN? MYOyNlYzPzJ7NB?=
A549 NEfYd2RHfW6ldHnvckBCe3OjeR?= NV7qVIprOTEEoN88UeKh MUSxJIg> M1X0cZN2eHC{ZYPz[ZMhVmGwbz3Dc{1qdmS3Y3XkJJA2OyCjY3P1cZVt[XSrb36= MlHDNlI2PTl|MkG=
T47D  NEe1R2JHfW6ldHnvckBCe3OjeR?= NUfPdWJTOjEEoH3N NV;5OmtYOjRiaB?= M2X2SmROW09? NYjBd2N7eHKndnXueJMhUVJvaX7keYNm\CCmZXfyZYRifGmxbjDv[kBK|rqEzsG= MmnrNlEyPDR6MEW=
A29 MEF MoLXSpVv[3Srb36gRZN{[Xl? NILoXXIyOMLizszNxsA> MojaNYg> MlTiZoxw[2u|wrD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGtdDDheEBU\XJ2N{RCpC=> NYC2UIJnOjByNUO3PFE>
MDA-MB-453  MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXPb|FuPS12MDFOwG0> MlPqO|IhcA>? NYfRbo9ZUUN3MDDv[kAyOCEQvF2= MXKyNFA2Ozd6MR?=
PC-3 NX[5TXFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fT[lUuPDBizszN NXPpfIhzPzJiaB?= NV;VRXBzUUN3MDDv[kAyOCEQvF2= M2TiUFIxODV|N{ix

... Click to View More Cell Line Experimental Data

In vivo Suppression of ATM-dependent STAT3 activation by KU-55933 enhances TRAIL-mediated apoptosis through up-regulation of surface DR5 expression, whereas suppression of both STAT3 and NF-κB appeares to be involved in down-regulation of cFLIP accompanied by an additional increase in apoptotic levels. The ATM inhibitor KU-55933 affectes TRAIL-mediated apoptosis more strongly than the JAK2 inhibitor, AG490, or overexpression of STAT3β. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Purified enzyme assays:

ATM for use in the in vitro assay is obtained from HeLa nuclear extract by immunoprecipitation with rabbit polyclonal antiserum raised to the COOH-terminal 400 amino acids of ATM in buffer containing 25 mM HEPES (pH 7.4), 2 mM MgCl2, 250 mM KCl, 500 μM EDTA, 100 μM Na3VO4, 10% v/v glycerol, and 0.1% v/v Igepal. ATM-antibody complexes are isolated from nuclear extract by incubating with protein A-Sepharose beads for 1 hour and then through centrifugation to recover the beads. In the well of a 96-well plate, ATM-containing Sepharose beads are incubated with 1 μg of substrate glutathione S-transferase–p53N66 (NH2-terminal 66 amino acids of p53 fused to glutathione S-transferase) in ATM assay buffer [25 mM HEPES (pH 7.4), 75 mM NaCl, 3 mM MgCl2, 2 mM MnCl2, 50 μM Na3VO4, 500 μM DTT, and 5% v/v glycerol] at 37 °C in the presence or absence of inhibitor. After 10 minutes with gentle shaking, ATP is added to a final concentration of 50 μM and the reaction continued at 37 °C for an additional 1 hour. The plate is centrifuged at 250 × g for 10 minutes (4 °C) to remove the ATM-containing beads, and the supernatant is removed and transferred to a white opaque 96-well plate and incubated at room temperature for 1.5 hours to allow glutathione S-transferase-p53N66 binding. This plate is then washed with PBS, blotted dry, and analyzed by a standard ELISA technique with a phospho-serine 15 p53 antibody. The detection of phosphorylated glutathione S-transferase-p53N66 substrate is performed in combination with a goat antimouse horseradish peroxidase-conjugated secondary antibody. Enhanced chemiluminescence solution is used to produce a signal and chemiluminescent detection is carried out.
Cell Research:

[1]

+ Expand
  • Cell lines: U2OS cells
  • Concentrations: 10 μM
  • Incubation Time: 2 hours
  • Method:

    U2OS cells are exposed to ionizing radiation (3, 5, or 15 Gy) or UV (5 or 50 J/m2) and the ATM response determined by Western blot analysis of p53 serine 15 phosphorylation and stabilization of wild-type p53. Whole cell extracts are obtained from each time point, proteins separated by SDS-PAGE, and the ATM-specific increase in phosphorylated serine 15 measured with a p53 phospho-serine 15 specific antibody. Overall p53 stabilization with time is also observed with a p53-specific antibody (DO-1). Similarly, for studying ATM-dependent phosphorylations on H2AX, CHK1, NBS1, and SMC1, the following antibodies are used: CHK1 phospho-serine 345 and NBS1 phospho-serine 343 antibodies. Histone H2A (H-124) and CHK1 antibodies are also used, as well as SMC1 and SMC1 phospho-serine 966 antibodies. For determination of a cellular IC50 for KU-55933, the peak response time for p53 serine 15 phosphorylation of 2 hours is used to monitor inhibition of ATM. KU-55933 is titrated onto cells and preincubated for 1 hour before ionizing radiation. Using scanning densitometry, the percentage inhibition relative to vehicle control is calculated, and the IC50 value is calculated as for the in vitro determinations.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: BALB/c nu/nu nude mice bearing LU1205 cells
  • Formulation: --
  • Dosages: 10 μM
  • Administration: --
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 33 mg/mL (83.44 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO and 47.5% PEG300
For best results, use promptly after mixing.
10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 395.49
Formula

C21H17NO3S2

CAS No. 587871-26-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATM/ATR Signaling Pathway Map

ATM/ATR Inhibitors with Unique Features

Related ATM/ATR Products

Tags: buy KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) supplier | purchase KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) cost | KU-55933 (ATM Kinase Inhibitor) manufacturer | order KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID